Genomic Vision

Financial Information for the Third Quarter of 2023 - Seite 2

As of September 30, 2023, Genomic Vision had cash and cash equivalents amounting to €50 thousand compared to €0.76 million on December 31, 2022. The Company’s use of cash is attributable to the day-to-day activities and the gradual implementation of its strategic plan.

Given the evolution of its share price and the liquidity of the shares on the market, Genomic Vision was no longer able to cover all of its cash needs. To date, the Company reports current liabilities and does not have sufficient available resources to meet them.
In this context, the Company has requested on November 3, 2023, the opening of receivership proceedings (“procédure de redressement judiciaire”) with the Commercial Court of Nanterre.

The Commercial Court of Nanterre will rule on this request for the opening of receivership proceedings during a hearing to be held on November 15, 2023. If the Commercial Court grants the Company's request, the Company will continue its current activities during the observation period of a duration set by the Court. The Court may decide to open liquidation proceedings if it considers that the financing of an observation period is not assured.

The suspension of the listing of Genomic Vision shares, effective since November 6, is maintained until further notice.

Upcoming financial publications²

• Financial information for the 4^th quarter of 2023: February 29, 2024
• Annual results 2023: March 22, 2024

***

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company that develops products and services for the highly accurate characterization of genome modifications. We deliver high-quality integrated genomic analysis solutions to improve quality control and bioproduction standards of advanced gene therapies at scale. Based on molecular combing technology and artificial intelligence, The Company provides robust quantitative measurements needed for high confidence characterization of transformed cell lines and prediction of cell line performance, in particular in the context of the biomanufacturing processes of cell and gene therapies. Genomic Vision’s molecular combing technology has further applications in drug development of agents targeting DNA replication and damage response mechanisms, visualizing DNA replication kinetics and telomere length maintenance. Genomic Vision, based near Paris in Bagneux, is a public company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).